Soluble Lectin-Like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients With Metabolic Syndrome

• Published in: Journal of clinical laboratory analysis Vol. 29; no. 3; pp. 184 - 190
• Main Authors: Civelek, S., Kutnu, M., Uzun, H., Erdenen, F., Altunoglu, E., Andican, G., Seven, A., Sahin, A. O., Burcak, G.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.05.2015; John Wiley & Sons, Inc; John Wiley and Sons Inc
• Subjects: Adult; Aryldialkylphosphatase - blood; Body Mass Index; Diabetes; endothelial nitric oxide synthase; endothelin-1; Endothelin-1 - blood; Female; Humans; Lipoproteins, LDL - blood; Logistic Models; Low density lipoprotein; Male; Metabolic Diseases - blood; Metabolic Diseases - metabolism; Metabolic syndrome; Middle Aged; Nitric oxide; Nitric Oxide - blood; Nitric Oxide Synthase Type III - blood; Original; oxidized LDL; ROC Curve; Scavenger Receptors, Class E - blood; soluble lectin-like oxidized LDL receptor 1; metabolic syndrome; endothelial nitric oxide synthase; nitric oxide; oxidized LDL; soluble lectin-like oxidized LDL receptor 1; endothelin-1
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.21748

Background Metabolic syndrome (MetS) defines a well‐known cluster of metabolic disturbances associated with an increased risk of cardiovascular disease and diabetes. The aim of this study was to examine the distribution of soluble lectin‐like oxidized low‐density lipoprotein (LDL) receptor‐1 (sLOX‐1) levels in patients with MetS, possible association of sLOX‐1 with oxidized LDL (oxLDL), endothelial nitric oxide synthase (eNOS), nitric oxide (NOx), endothelin‐1 (ET‐1), paraoxonase 1 (PON1), and arylesterase (ARE) activities, and these parameters compared with healthy controls. Methods A total of 55 patients (37 women, 18 men) with MetS and 29 healthy controls (19 women, 10 men) with a body mass index (BMI) less than 25 kg/m2 were enrolled in the study. Results sLOX‐1, oxLDL, and ET‐1 levels were significantly higher in patients with MetS than in control subjects (P = 0.023 P < 0.001, and P < 0.001, respectively). MetS patients have significantly lower eNOS and NOx levels, and PON1 and ARE activities than control subjects (P = 0.017, P < 0.004, P < 0.001, and P = 0.010, respectively). A positive correlation was observed between the sLOX‐1 levels and the oxLDL, ET‐1, BMI, glucose levels. ET‐1 levels also exhibited significant negative correlation with ARE activity. Conclusion sLOX‐1 levels are associated with cardiovascular risk factors, such as increased oxLDL, obesity, and diabetes, in patients with MetS. An increased concentration of sLOX‐1 could be an early predictor of endothelial damage in MetS. In addition, it appears that oxLDL, ET‐1, eNOS, NOx, PON1, and ARE activities may accurately reflect the levels of endothelial dysfunction in MetS patients.